Latest Pharma and Biotech News
Generics
16 June 2026 India is grappling with a severe shortage of two cornerstone chemotherapy drugs, cisplatin and carboplatin, as soaring platinum prices, higher import duties, and regulatory delays make production financially unsustainable.
Today's issue
Refine search
Biotechnology
US biotech Protillion Biosciences has entered a multi-target discovery collaboration and license agreement with pharma major Merck & Co. 16 June 2026
Biotechnology
Moderna today announced changes to its operating model to support its short- and long-term business goals, with the news sending the US mRNA vaccines firm’s shares up 3.5% to $53.97 by mid-morning. 16 June 2026
Generics
India is grappling with a severe shortage of two cornerstone chemotherapy drugs, cisplatin and carboplatin, as soaring platinum prices, higher import duties, and regulatory delays make production financially unsustainable. 16 June 2026
Biotechnology
San Diego, USA-based Soleno Therapeutics, which has just been acquired by Neurocrine Biosciences, has announced late-breaking data at ENDO 2026 showing that resuming treatment with Vykat XR (diazoxide choline) extended-release tablets . 16 June 2026
Pharmaceutical
Japanese pharma Takeda has reported further Phase III data showing that oveporexton improved daily function, cognition and nighttime sleep in people with narcolepsy type 1 (NT1), adding to the case for a drug that could become the first approved orexin agonist for the disorder. 16 June 2026
Biotechnology
Swiss contract development and manufacturing organization (CDMO) Lonza Group has signed an exclusive, target-specific licensing agreement with US biotech Antharis Therapeutics to develop dual-payload antibody-drug conjugates (ADCs) for gastrointestinal (GI) cancers. 16 June 2026
Biotechnology
Shares of Australian biotech Dimerix leapt 21.2% to A$0.20 today on the news of a landmark licensing deal. 16 June 2026
Pharmaceutical
German neuroscience company HMNC Brain Health has raised $50 million in the first closing of a Series B financing round and signed a strategic partnership with Medice covering European commercialization of its oral ketamine program. 16 June 2026
Biotechnology
South Korea’s Fosun Pharmaceutical announced that its self-developed MEK 1/2 selective inhibitor luvometinib tablets (trade name: Fumaining) has been officially approved by China’s National Medical Products Administration (NMPA). 16 June 2026
Pharmaceutical
US pharma major Eli Lilly says Jaypirca (pirtobrutinib) cut the risk of disease progression or death by 45% when added to venetoclax and rituximab in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. 16 June 2026
Biotechnology
US biotech Neumora Therapeutics is discontinuing development of navacaprant in major depressive disorder after two Phase III studies failed, dealing a heavy blow to what had been its lead program. 16 June 2026
Pharmaceutical
US biotech Conexeu Sciences has added three directors to its board and named co-founder David Bogart as chief commercial officer, as the newly listed company looks to put more commercial muscle behind its regenerative tissue platform. 16 June 2026
Biotechnology
UK data and analytics group GlobalData says immunology and neurology drug development is entering a more targeted era, as companies move beyond older treatment classes and toward biologics, gene therapies and other precision approaches. 16 June 2026
Biotechnology
New Jersey, USA-based biotech Reunion Neuroscience has appointed Dr Sahil Kirpekar as its new president, chief executive (CEO) and a member of the board of Ddirectors, effective immediately. 16 June 2026
Pharmaceutical
Russia may revise the patent protection terms for drugs with aim to reduce their length from the current 25 years to 15-20 years or even lower. 16 June 2026
Biotechnology
German biotech company Vivoryon Therapeutics is rebuilding its story around diabetic kidney disease. 15 June 2026
Pharmaceutical
Barcelona, Spain-based Grifols today announced the US launch of its new fibrinogen concentrate. 15 June 2026
Biotechnology
Elicio Therapeutics saw its shares plummet nearly 74% to $3.92 in early trading today, after it reported results from its randomized Phase II AMPLIFY-7P study evaluating ELI-002 7P in patients with adjuvant mKRAS-driven pancreatic ductal adenocarcinoma (PDAC) following completion of standard locoregional therapy. 15 June 2026
Pharmaceutical
US biopharma Neurocrine Biosciences has reported new two-year data for Crenessity (crinecerfont), showing sustained reductions in disease biomarkers, lower glucocorticoid dosing and improvements in clinical measures among children and adolescents with classic congenital adrenal hyperplasia (CAH). 15 June 2026
Biotechnology
US pharma major Johnson & Johnson has reported positive Phase III data for Talvey (talquetamab-tgvs) in combination with Darzalex Faspro (daratumumab and hyaluronidase-fihj), with or without pomalidomide, in relapsed or refractory multiple myeloma patients who had received at least one prior line of therapy. 15 June 2026
All news
Pharmaceutical
The Ireland-based subsidiary of Indian drugmaker Glenmark Pharmaceuticals today announced the launch of Winlevi (clascoterone 10mg/g cream) across key markets in Europe. 11 June 2026
Generics
Spanish pharma Reig Jofre has launched dalbavancin in Europe, adding a long-acting injectable antibiotic to its hospital anti-infectives portfolio as cheaper versions begin to reshape a specialized market. 11 June 2026
Pharmaceutical
Outsourced manufacturing has become part of the basic infrastructure of the pharma industry. Large drugmakers use it for flexibility, specialist capacity and regional supply. Smaller biotechs use it because most cannot build plants of their own. 11 June 2026
Pharmaceutical
The global branded drug industry has urged G7 leaders to put pharmaceutical innovation at the center of their economic agenda, in a pre-summit statement that also serves as a clear pitch for policies more favorable to the sector. 11 June 2026
Pharmaceutical
US pharma giant Pfizer is reviewing the timing and scope of planned investments in Germany, as industry anger builds over proposed healthcare reforms that could lower drug prices in one of Europe’s largest pharma markets. 11 June 2026
Pharmaceutical
Shares of Harrow Health closed up 9% at $36.47 yesterday, after it announced the re-launch of Verkazia (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy for vernal keratoconjunctivitis (VKC), a serious allergic eye disease affecting children and adults. 11 June 2026
Biotechnology
UK biotech PhoreMost today announced its lead program, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers. 10 June 2026
Biotechnology
Orionis Biosciences, a privately held, clinical-stage life sciences company pioneering proximity-induced therapeutic modalities, today announced a multi-year collaboration with Swiss pharma giant Novartis to discover and design molecular glue drugs for challenging therapeutic targets across multiple disease areas. 10 June 2026
Biotechnology
Cambridge, Massachusetts-based Ethyreal Bio has launched with $101 million in financing to advance ETHY-001, a preclinical antibody being developed for Graves’ disease and thyroid eye disease (TED). 10 June 2026
Biotechnology
San Francisco-based biotech SonoThera today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines. 10 June 2026
Biotechnology
Norwegian biotech company Circio Holding has raised 300 million Norwegian krone ($31.5 million) through the exercise of warrants and an underwritten private placement, extending its cash runway to the end of 2030. 10 June 2026
Biotechnology
Biotech companies are still being formed around university science, venture funding and experienced management teams. But the route from scientific idea to new company is changing, and the shift is now visible across the USA, Europe, China and other major innovation hubs. 10 June 2026
Biotechnology
French pharma major Sanofi today announced that the riliprubart MOBILIZE Phase III study in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment will be stopped. Sanofi’s shares dipped 1.6% to $75.82 euros on the news. 10 June 2026
Pharmaceutical
French drugmaker Servier has entered a strategic collaboration with the USA-based n-Lorem Foundation to advance research into rare neurodevelopmental disorders using antisense oligonucleotide (ASO) technology. 10 June 2026
Pharmaceutical
Portuguese drugmaker Bial is discontinuing development of pariceract (BIA 28-6156) for GBA1-associated Parkinson’s disease after the investigational therapy failed to meet the primary and key secondary efficacy endpoints in the Phase IIb ACTIVATE study. 10 June 2026
Biotechnology
US biotech Parabilis Medicines is set to raise $745 million from a blockbuster initial public offering and concurrent private placement, in what appears to be the largest biotech IPO on record. 10 June 2026
Pharmaceutical
Australia’s Therapeutic Goods Administration (TGA) has expanded its priority focus areas to include unapproved peptide products, following increased detection of unlawful importation, supply and advertising, posing potential risks to consumer safety. 10 June 2026
Biotechnology
German biotech CatalYm has appointed Peter Garcia as chief financial officer, adding a seasoned life sciences finance executive as its lead asset, visugromab, moves through a broad mid- to late-stage clinical program. 10 June 2026
Biotechnology
Swedish rare diseases company Hansa Biopharma today announced that Fredrik Röök has been appointed as vice president business development effective August 17. 10 June 2026
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review Japan’s largest drugmaker Takeda’s supplemental Biologics License Application (sBLA) for intravenous (IV) Entyvio vedolizumab) for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease in pediatric patients aged 2 years and older. 10 June 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze